REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Leerink Partnrs lowered their FY2024 EPS estimates for shares of REGENXBIO in a note issued to investors on Wednesday, February 19th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings per share of ($4.93) for the year, down from their previous forecast of ($4.86). The consensus estimate for REGENXBIO's current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO's Q4 2024 earnings at ($1.34) EPS, FY2025 earnings at ($1.57) EPS, FY2026 earnings at ($1.25) EPS, FY2027 earnings at ($1.88) EPS, FY2028 earnings at ($0.65) EPS and FY2029 earnings at $0.23 EPS.
A number of other research analysts also recently issued reports on RGNX. StockNews.com downgraded shares of REGENXBIO from a "hold" rating to a "sell" rating in a research report on Saturday, February 15th. Morgan Stanley reiterated an "overweight" rating and issued a $22.00 price objective on shares of REGENXBIO in a research note on Friday, November 15th. The Goldman Sachs Group lowered shares of REGENXBIO from a "buy" rating to a "neutral" rating and decreased their price target for the company from $38.00 to $14.00 in a research note on Tuesday, February 11th. Royal Bank of Canada restated an "outperform" rating and set a $30.00 price target on shares of REGENXBIO in a research note on Tuesday, January 21st. Finally, HC Wainwright reiterated a "buy" rating and issued a $36.00 target price on shares of REGENXBIO in a research note on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $33.45.
Get Our Latest Analysis on RGNX
NASDAQ:RGNX opened at $7.27 on Monday. The firm's 50 day simple moving average is $7.70 and its 200 day simple moving average is $9.59. REGENXBIO has a one year low of $6.56 and a one year high of $28.80. The company has a market cap of $360.16 million, a PE ratio of -1.45 and a beta of 1.29.
A number of large investors have recently added to or reduced their stakes in RGNX. FMR LLC increased its stake in REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 1,656 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of REGENXBIO by 9.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company's stock worth $185,000 after buying an additional 1,982 shares during the period. Teacher Retirement System of Texas lifted its holdings in shares of REGENXBIO by 19.9% in the 4th quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company's stock worth $97,000 after buying an additional 2,088 shares during the period. DnB Asset Management AS lifted its holdings in shares of REGENXBIO by 20.1% in the 4th quarter. DnB Asset Management AS now owns 14,539 shares of the biotechnology company's stock worth $112,000 after buying an additional 2,434 shares during the period. Finally, GAMMA Investing LLC lifted its stake in shares of REGENXBIO by 273.1% during the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 2,510 shares during the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.